Keywords
in vitro bioequivalence profiles
dissolution test
Kisangani market
How to Cite
Abstract
Introduction
Phenoxymethylpenicillin is commonly presented in various generic forms and rarely as proprietary brands. Given the prevalence of counterfeit products and the increased use of generic drugs in sub-Saharan Africa, ensuring drug quality is critical to meet legal requirements for bioequivalence and interchangeable dispensation.
Purpose
The purpose of this in vitro study was to meticulously compare the bioequivalence of 250 mg generic Penicillin V tablets with an originator brand marketed in Kisangani, focusing on physicochemical properties and dissolution kinetics based on European Medicines Agency (EMA) standards and USP Pharmacopoeia (USP 43-NF 38, 2013) guidelines.
Methods
Identification and assay were performed using a UV-visible spectrophotometer, and dissolution kinetics were conducted at pH levels of 1.2, 4.5, and 6.8 with appropriate dissolution equipment. The fit factor method was applied to compare dissolution profiles across these pH levels.
Results
The findings are significant, revealing that while the generic tablets weighed half as much (340 mg) as the originator tablets (770 mg), both showed acceptable mass uniformity and contained approximately 250 mg of active ingredient. Dissolution profiles were comparable, with difference factors (f1) < 15 and similarity factors (f2) > 50. In acidic media (pH 1.2 and 4.5), full release occurred in under 15 minutes, while in basic intestinal-type medium (pH 6.8), an 80% release rate was observed.
Conclusion
These results support the interchangeability of the generic and originator Penicillin V products, while potential in vivo variations cannot be ruled out.
References
Abelli, C., & Becart, A. (2009). Test de dissolutions appliqué aux formes orales immédiates. STP Pharma Pratiques, 9, 310–315.
Abelli, C., et al. (2001). Equivalence pharmaceutique des médicaments essentiels génériques. STP Pharma Pratiques, 11, 89–101.
Brossard, D. (2006). L’essai de vitesse de dissolution, pourquoi? Comment? STP Pharma Pratiques, 19, 819–727.
Cardenas, J. (2016). Révision médicale: Directeur médical de Doctissimo.
Even-Adin, D., De Muylder, I. .A., & Sternon, J. (2002). The generic forms: Similarities, bioequivalence but no conformity. Journal de Pharmacie de Belgique, Association Pharmaceutique Belge, Bruxelles, Belgique, 57, 14–20.
Grace, A. G., Santosh, J. W., David, J. I., Dejian, M., Richard, F. J., Gregory, L. K., Hassan, A. (2019). Bioavailability testing of a newly developed clindamycin oral suspension in a pediatric porcine model. Pharmaceutical Development and Technology, 24(8), 1038–1043.
Mahano, A. O., Mahano, A. Z., Cubaka, N. H., Kasali, F. M., Bavurhe, B. Z, Murhula, L. N., Murhula, P. H. & Kadima, N. J. (2021). Pharmaceutical quality of antimalarial drugs: Quinine sulfate and Artemether/Lumefantrine tablets sold on Bukavu market. Future Journal of Pharmaceutical Sciences, 7, 131.
Moreno, R. A., Boldrina L., Guermani, A., Mazucheli, J., Sverdloff, C., & Borges, N. C. (2007). Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 45, 669–676.
Najia, R., & Naqvi, S. B. S. (2024). In vitro-in vivo extrapolation and bioequivalence prediction for immediate-release capsules of cephadroxil based on a physiologically based pharmacokinetic ACAT model. AAPS PharmSciTech, 25, 100.
Naseem, A. C., Ziyaur, R., & Areeg, A. A. (2018). Is the demonstration of bioequivalence of clavulanic acid required in amoxicillin-clavulanic acid orally administrated immediate-release products? Journal of Pharmacy and Pharmacology, 70(7), 883–892.
Niwa, T., Hata T., Hayashi, M., & Imagawa, Y (2016). Evaluation of the pharmacokinetic parameters of standard oral antibiotics in a bioequivalence study of generic products. Pharmazie, 71, 363–377.
Piovani, D., Clavenna A., Cartabia M., Bortolotti A., Fortino I., Merlino L., & Bonati M. (2015). Comparing recurrent antibiotic prescriptions in children treated with a brand name or generic formulation. Pharmacology and Drug Safety, 24, 121–128.
Sawaya, A. (2012). Rapport de l’Agence nationale de la sécurité du médicament et des produits de santé: Les médicaments génériques; médicament à part entière. Saint Denis Cedex, 16–51.
Urbach, A. (2017). Betalactames bicycliques pontes (N1-C3): Synthèse et évaluation théorique, chimique et biochimique. In Marchand-Brynaert, J. https://hdl.handle.net/2078.1/5338
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.